BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma J, Zhou Q, Li H. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. Nutrients. 2017;9. [PMID: 29035308 DOI: 10.3390/nu9101124] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 20.0] [Reference Citation Analysis]
Number Citing Articles
1 Khan A, Ding Z, Ishaq M, Bacha AS, Khan I, Hanif A, Li W, Guo X. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates. Int J Biol Sci 2021;17:818-33. [PMID: 33767591 DOI: 10.7150/ijbs.56214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
2 Chakraborty D, Wang J. Nonalcoholic fatty liver disease and colorectal cancer: Correlation and missing links. Life Sci 2020;262:118507. [PMID: 33017572 DOI: 10.1016/j.lfs.2020.118507] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Álvarez-Mercado AI, Navarro-Oliveros M, Robles-Sánchez C, Plaza-Díaz J, Sáez-Lara MJ, Muñoz-Quezada S, Fontana L, Abadía-Molina F. Microbial Population Changes and Their Relationship with Human Health and Disease. Microorganisms 2019;7:E68. [PMID: 30832423 DOI: 10.3390/microorganisms7030068] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 14.0] [Reference Citation Analysis]
4 Kim H, Lee DS, An TH, Park HJ, Kim WK, Bae KH, Oh KJ. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. Int J Mol Sci 2021;22:4495. [PMID: 33925827 DOI: 10.3390/ijms22094495] [Reference Citation Analysis]
5 Houttu V, Boulund U, Grefhorst A, Soeters MR, Pinto-Sietsma SJ, Nieuwdorp M, Holleboom AG. The role of the gut microbiome and exercise in non-alcoholic fatty liver disease. Therap Adv Gastroenterol 2020;13:1756284820941745. [PMID: 32973925 DOI: 10.1177/1756284820941745] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
6 Monga Kravetz A, Testerman T, Galuppo B, Graf J, Pierpont B, Siebel S, Feinn R, Santoro N. Effect of Gut Microbiota and PNPLA3 rs738409 Variant on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Youth. J Clin Endocrinol Metab 2020;105:dgaa382. [PMID: 32561908 DOI: 10.1210/clinem/dgaa382] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
7 Li R, Yao Y, Gao P, Bu S. The Therapeutic Efficacy of Curcumin vs. Metformin in Modulating the Gut Microbiota in NAFLD Rats: A Comparative Study. Front Microbiol 2020;11:555293. [PMID: 33584555 DOI: 10.3389/fmicb.2020.555293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chen HT, Huang HL, Li YQ, Xu HM, Zhou YJ. Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view. World J Gastroenterol 2020; 26(16): 1901-1911 [PMID: 32390701 DOI: 10.3748/wjg.v26.i16.1901] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
9 Dao D, Xie B, Nadeem U, Xiao J, Movahedan A, D'Souza M, Leone V, Hariprasad SM, Chang EB, Sulakhe D, Skondra D. High-Fat Diet Alters the Retinal Transcriptome in the Absence of Gut Microbiota. Cells 2021;10:2119. [PMID: 34440888 DOI: 10.3390/cells10082119] [Reference Citation Analysis]
10 Zhao Z, Wang C, Zhang L, Zhao Y, Duan C, Zhang X, Gao L, Li S. Lactobacillus plantarum NA136 improves the non-alcoholic fatty liver disease by modulating the AMPK/Nrf2 pathway. Appl Microbiol Biotechnol 2019;103:5843-50. [DOI: 10.1007/s00253-019-09703-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
11 Soto-Angona Ó, Anmella G, Valdés-Florido MJ, De Uribe-Viloria N, Carvalho AF, Penninx BWJH, Berk M. Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches. BMC Med 2020;18:261. [PMID: 32998725 DOI: 10.1186/s12916-020-01713-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
12 Gadallah SH, Eissa S, Ghanem HM, Ahmed EK, Hasanin AH, El Mahdy MM, Matboli M. Probiotic-prebiotic-synbiotic modulation of (YAP1, LATS1 and NF2 mRNAs/miR-1205/lncRNA SRD5A3-AS1) panel in NASH animal model. Biomed Pharmacother 2021;140:111781. [PMID: 34090052 DOI: 10.1016/j.biopha.2021.111781] [Reference Citation Analysis]
13 Jin H, Xu X, Pang B, Yang R, Sun H, Jiang C, Shao D, Shi J. Probiotic and prebiotic interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. Benef Microbes 2021;:1-14. [PMID: 34511051 DOI: 10.3920/BM2020.0183] [Reference Citation Analysis]
14 Pongpirul K, Janchot K, Dai Y. Single strain probiotics for dyslipidemia, fatty liver, and obesity: A systematic review and meta-analysis. World J Meta-Anal 2019; 7(6): 323-338 [DOI: 10.13105/wjma.v7.i6.323] [Reference Citation Analysis]
15 Zhong Y, Song B, Zheng C, Zhang S, Yan Z, Tang Z, Kong X, Duan Y, Li F. Flavonoids from Mulberry Leaves Alleviate Lipid Dysmetabolism in High Fat Diet-Fed Mice: Involvement of Gut Microbiota. Microorganisms 2020;8:E860. [PMID: 32517288 DOI: 10.3390/microorganisms8060860] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
16 Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, Carmona-Sánchez R, González-Huezo MS, García-Juárez I, Chávez-Tapia N, Aguilar-Salinas C, Aiza-Haddad I, Ballesteros-Amozurrutia MA, Bosques-Padilla F, Castillo-Barradas M, Chávez-Barrera JA, Cisneros-Garza L, Flores-Calderón J, García-Compeán D, Gutiérrez-Grobe Y, Higuera de la Tijera MF, Kershenobich-Stalnikowitz D, Ladrón de Guevara-Cetina L, Lizardi-Cervera J, López-Cossio JA, Martínez-Vázquez S, Márquez-Guillén E, Méndez-Sánchez N, Moreno-Alcantar R, Poo-Ramírez JL, Ramos-Martínez P, Rodríguez-Hernández H, Sánchez-Ávila JF, Stoopen-Rometti M, Torre-Delgadillo A, Torres-Villalobos G, Trejo-Estrada R, Uribe-Esquivel M, Velarde-Ruiz Velasco JA. The Mexican consensus on nonalcoholic fatty liver disease.Rev Gastroenterol Mex (Engl Ed). 2019;84:69-99. [PMID: 30711302 DOI: 10.1016/j.rgmx.2018.11.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
17 Higarza SG, Arboleya S, Gueimonde M, Gómez-Lázaro E, Arias JL, Arias N. Neurobehavioral dysfunction in non-alcoholic steatohepatitis is associated with hyperammonemia, gut dysbiosis, and metabolic and functional brain regional deficits. PLoS One 2019;14:e0223019. [PMID: 31539420 DOI: 10.1371/journal.pone.0223019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
18 Carbajo-Pescador S, Porras D, García-Mediavilla MV, Martínez-Flórez S, Juarez-Fernández M, Cuevas MJ, Mauriz JL, González-Gallego J, Nistal E, Sánchez-Campos S. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an in vivo model of early obesity and non-alcoholic fatty liver disease. Dis Model Mech 2019;12:dmm039206. [PMID: 30971408 DOI: 10.1242/dmm.039206] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 17.0] [Reference Citation Analysis]
19 Ni Y, Ni L, Zhuge F, Fu Z. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease. Mol Nutr Food Res 2020;64:e2000375. [PMID: 32738185 DOI: 10.1002/mnfr.202000375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
20 John OD, Mouatt P, Majzoub ME, Thomas T, Panchal SK, Brown L. Physiological and Metabolic Effects of Yellow Mangosteen (Garcinia dulcis) Rind in Rats with Diet-Induced Metabolic Syndrome. Int J Mol Sci 2019;21:E272. [PMID: 31906096 DOI: 10.3390/ijms21010272] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
21 Li Y, Yi J, Zeng Q, Liu Y, Yang B, Liu B, Li Y, Mehmood K, Hussain R, Tang Z, Zhang H, Li Y. Zearalenone exposure mediated hepatotoxicity via mitochondrial apoptotic and autophagy pathways: Associated with gut microbiome and metabolites. Toxicology 2021;462:152957. [PMID: 34537261 DOI: 10.1016/j.tox.2021.152957] [Reference Citation Analysis]
22 Tsai YL, Lin TL, Chang CJ, Wu TR, Lai WF, Lu CC, Lai HC. Probiotics, prebiotics and amelioration of diseases. J Biomed Sci 2019;26:3. [PMID: 30609922 DOI: 10.1186/s12929-018-0493-6] [Cited by in Crossref: 76] [Cited by in F6Publishing: 63] [Article Influence: 38.0] [Reference Citation Analysis]
23 Khan MY, Mihali AB, Rawala MS, Aslam A, Siddiqui WJ. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019;31:703-15. [PMID: 31009401 DOI: 10.1097/MEG.0000000000001371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
24 Hegazy MA, Mogawer SM, Alnaggar ARLR, Ghoniem OA, Abdel Samie RM. Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH. Diabetes Metab Syndr Obes 2020;13:3861-72. [PMID: 33116732 DOI: 10.2147/DMSO.S249949] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Barré T, Rojas Rojas T, Lacombe K, Protopopescu C, Poizot-Martin I, Nishimwe ML, Zucman D, Esterle L, Billaud E, Aumaitre H, Bouchaud O, Rey D, Piroth L, Salmon-Ceron D, Wittkop L, Sogni P, Carrieri MP, Serfaty L, Marcellin F. Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH). Expert Rev Anti Infect Ther 2021;19:1147-56. [PMID: 33538612 DOI: 10.1080/14787210.2021.1884545] [Reference Citation Analysis]
26 O'Connell TM. The Application of Metabolomics to Probiotic and Prebiotic Interventions in Human Clinical Studies. Metabolites 2020;10:E120. [PMID: 32213886 DOI: 10.3390/metabo10030120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
27 Koopman N, Molinaro A, Nieuwdorp M, Holleboom AG. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019;50:628-639. [PMID: 31373710 DOI: 10.1111/apt.15416] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
28 Barrea L, Muscogiuri G, Annunziata G, Laudisio D, de Alteriis G, Tenore GC, Colao A, Savastano S. A New Light on Vitamin D in Obesity: A Novel Association with Trimethylamine-N-Oxide (TMAO). Nutrients 2019;11:E1310. [PMID: 31185686 DOI: 10.3390/nu11061310] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 16.0] [Reference Citation Analysis]
29 Oh JH, Lee JH, Cho MS, Kim H, Chun J, Lee JH, Yoon Y, Kang W. Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease. Nutrients 2021;13:1013. [PMID: 33801023 DOI: 10.3390/nu13031013] [Reference Citation Analysis]
30 Rinninella E, Mele MC, Merendino N, Cintoni M, Anselmi G, Caporossi A, Gasbarrini A, Minnella AM. The Role of Diet, Micronutrients and the Gut Microbiota in Age-Related Macular Degeneration: New Perspectives from the Gut⁻Retina Axis. Nutrients 2018;10:E1677. [PMID: 30400586 DOI: 10.3390/nu10111677] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 14.7] [Reference Citation Analysis]
31 Perez-Carrasco V, Soriano-Lerma A, Soriano M, Gutiérrez-Fernández J, Garcia-Salcedo JA. Urinary Microbiome: Yin and Yang of the Urinary Tract. Front Cell Infect Microbiol 2021;11:617002. [PMID: 34084752 DOI: 10.3389/fcimb.2021.617002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Konturek PC, Harsch IA, Konturek K, Schink M, Konturek T, Neurath MF, Zopf Y. Gut⁻Liver Axis: How Do Gut Bacteria Influence the Liver? Med Sci (Basel) 2018;6:E79. [PMID: 30227645 DOI: 10.3390/medsci6030079] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 11.0] [Reference Citation Analysis]
33 Li Y, Wang C, Lu J, Huang K, Han Y, Chen J, Yang Y, Liu B. PPAR δ inhibition protects against palmitic acid-LPS induced lipidosis and injury in cultured hepatocyte L02 cell. Int J Med Sci 2019;16:1593-603. [PMID: 31839747 DOI: 10.7150/ijms.37677] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
34 Subramaniam A, Landstrom M, Hayes KC. Genetic Permissiveness and Dietary Glycemic Load Interact to Predict Type-II Diabetes in the Nile rat (Arvicanthis niloticus). Nutrients 2019;11:E1538. [PMID: 31284621 DOI: 10.3390/nu11071538] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
35 Chen LJ, He JT, Pan M, Liu JL, Zhang KK, Li JH, Wang LB, Xu LL, Chen YK, Zhang QY, Li DR, Xu JT, Xie XL. Antibiotics Attenuate Methamphetamine-Induced Hepatotoxicity by Regulating Oxidative Stress and TLR4/MyD88/Traf6 Axis. Front Pharmacol 2021;12:716703. [PMID: 34381368 DOI: 10.3389/fphar.2021.716703] [Reference Citation Analysis]
36 Zhang S, Fu J, Zhang Q, Liu L, Meng G, Yao Z, Wu H, Bao X, Gu Y, Lu M, Sun S, Wang X, Zhou M, Jia Q, Song K, Xiang H, Wu Y, Niu K. Association between nut consumption and non-alcoholic fatty liver disease in adults. Liver Int 2019;39:1732-41. [PMID: 31162803 DOI: 10.1111/liv.14164] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
37 Hadi A, Mohammadi H, Miraghajani M, Ghaedi E. Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD. Critical Reviews in Food Science and Nutrition 2019;59:2494-505. [DOI: 10.1080/10408398.2018.1458021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
38 Yang M, Geng CA, Liu X, Guan M. Lipid Disorders in NAFLD and Chronic Kidney Disease. Biomedicines 2021;9:1405. [PMID: 34680522 DOI: 10.3390/biomedicines9101405] [Reference Citation Analysis]
39 Ghosh S, Yang X, Wang L, Zhang C, Zhao L. Active phase prebiotic feeding alters gut microbiota, induces weight-independent alleviation of hepatic steatosis and serum cholesterol in high-fat diet-fed mice. Comput Struct Biotechnol J 2021;19:448-58. [PMID: 33510856 DOI: 10.1016/j.csbj.2020.12.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Azarang A, Farshad O, Ommati MM, Jamshidzadeh A, Heydari R, Abootalebi SN, Gholami A. Protective Role of Probiotic Supplements in Hepatic Steatosis: A Rat Model Study.Biomed Res Int. 2020;2020:5487659. [PMID: 33299871 DOI: 10.1155/2020/5487659] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
41 Yan R, Yang Y, Chen Y. Pharmacokinetics of Chinese medicines: strategies and perspectives. Chin Med 2018;13:24. [PMID: 29743935 DOI: 10.1186/s13020-018-0183-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
42 Chen K, Ma J, Jia X, Ai W, Ma Z, Pan Q. Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans. Biochim Biophys Acta Rev Cancer. 2019;1871:117-125. [PMID: 30528647 DOI: 10.1016/j.bbcan.2018.11.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
43 Jasirwan COM, Lesmana CRA, Hasan I, Sulaiman AS, Gani RA. The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms. Biosci Microbiota Food Health 2019;38:81-8. [PMID: 31384519 DOI: 10.12938/bmfh.18-032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
44 Ngowi EE, Wang YZ, Khattak S, Khan NH, Mahmoud SSM, Helmy YASH, Jiang QY, Li T, Duan SF, Ji XY, Wu DD. Impact of the factors shaping gut microbiota on obesity. J Appl Microbiol 2021. [PMID: 33570819 DOI: 10.1111/jam.15036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Duan M, Han ZH, Huang T, Yang Y, Huang B. Characterization of gut microbiota and short-chain fatty acid in breastfed infants with or without breast milk jaundice. Lett Appl Microbiol 2021;72:60-7. [PMID: 32893879 DOI: 10.1111/lam.13382] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 León IC, Quesada-Vázquez S, Sáinz N, Guruceaga E, Escoté X, Moreno-Aliaga MJ. Effects of Maresin 1 (MaR1) on Colonic Inflammation and Gut Dysbiosis in Diet-Induced Obese Mice. Microorganisms 2020;8:E1156. [PMID: 32751593 DOI: 10.3390/microorganisms8081156] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
47 Plaza-Díaz J, Solis-Urra P, Aragón-Vela J, Rodríguez-Rodríguez F, Olivares-Arancibia J, Álvarez-Mercado AI. Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis. Biomedicines 2021;9:145. [PMID: 33546191 DOI: 10.3390/biomedicines9020145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
48 Gao LL, Ma JM, Fan YN, Zhang YN, Ge R, Tao XJ, Zhang MW, Gao QH, Yang JJ. Lycium barbarum polysaccharide combined with aerobic exercise ameliorated nonalcoholic fatty liver disease through restoring gut microbiota, intestinal barrier and inhibiting hepatic inflammation. Int J Biol Macromol 2021;183:1379-92. [PMID: 33992651 DOI: 10.1016/j.ijbiomac.2021.05.066] [Reference Citation Analysis]
49 Risi R, Tuccinardi D, Mariani S, Lubrano C, Manfrini S, Donini LM, Watanabe M. Liver disease in obesity and underweight: the two sides of the coin. A narrative review. Eat Weight Disord 2020. [PMID: 33150534 DOI: 10.1007/s40519-020-01060-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
50 Chen H, Zhang F, Li R, Liu Y, Wang X, Zhang X, Xu C, Li Y, Guo Y, Yao Q. Berberine regulates fecal metabolites to ameliorate 5-fluorouracil induced intestinal mucositis through modulating gut microbiota. Biomed Pharmacother 2020;124:109829. [PMID: 31958765 DOI: 10.1016/j.biopha.2020.109829] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 16.0] [Reference Citation Analysis]
51 Kavyani M, Saleh-Ghadimi S, Dehghan P, Abbasalizad Farhangi M, Khoshbaten M. Co-supplementation of camelina oil and a prebiotic is more effective for in improving cardiometabolic risk factors and mental health in patients with NAFLD: a randomized clinical trial. Food Funct 2021. [PMID: 34338703 DOI: 10.1039/d1fo00448d] [Reference Citation Analysis]
52 Yang XF, Lu M, You L, Gen H, Yuan L, Tian T, Li CY, Xu K, Hou J, Lei M. Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology. Chin Med 2021;16:62. [PMID: 34315516 DOI: 10.1186/s13020-021-00470-x] [Reference Citation Analysis]
53 Baratta F, Pastori D, Bartimoccia S, Cammisotto V, Cocomello N, Colantoni A, Nocella C, Carnevale R, Ferro D, Angelico F, Violi F, Del Ben M. Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide are Associated with Oxidative Stress in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients 2020;12:E1732. [PMID: 32531941 DOI: 10.3390/nu12061732] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
54 Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2019;13:193-204. [PMID: 30791767 DOI: 10.1080/17474124.2019.1569513] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
55 Juárez-Fernández M, Porras D, García-Mediavilla MV, Román-Sagüillo S, González-Gallego J, Nistal E, Sánchez-Campos S. Aging, Gut Microbiota and Metabolic Diseases: Management through Physical Exercise and Nutritional Interventions. Nutrients 2020;13:E16. [PMID: 33374578 DOI: 10.3390/nu13010016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
56 Iannone LF, Preda A, Blottière HM, Clarke G, Albani D, Belcastro V, Carotenuto M, Cattaneo A, Citraro R, Ferraris C, Ronchi F, Luongo G, Santocchi E, Guiducci L, Baldelli P, Iannetti P, Pedersen S, Petretto A, Provasi S, Selmer K, Spalice A, Tagliabue A, Verrotti A, Segata N, Zimmermann J, Minetti C, Mainardi P, Giordano C, Sisodiya S, Zara F, Russo E, Striano P. Microbiota-gut brain axis involvement in neuropsychiatric disorders. Expert Rev Neurother 2019;19:1037-50. [PMID: 31260640 DOI: 10.1080/14737175.2019.1638763] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 21.5] [Reference Citation Analysis]
57 Guilbaud A, Howsam M, Niquet-Léridon C, Delguste F, Fremont M, Lestavel S, Maboudou P, Garat A, Schraen S, Onraed B, Foligné B, Boulanger É, Tessier FJ. The Effect of Lactobacillus fermentum ME-3 Treatment on Glycation and Diabetes Complications. Mol Nutr Food Res 2020;64:e1901018. [PMID: 31991062 DOI: 10.1002/mnfr.201901018] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
58 Leong KSW, Jayasinghe TN, Derraik JGB, Albert BB, Chiavaroli V, Svirskis DM, Beck KL, Conlon CA, Jiang Y, Schierding W, Vatanen T, Holland DJ, O'Sullivan JM, Cutfield WS. Protocol for the Gut Bugs Trial: a randomised double-blind placebo-controlled trial of gut microbiome transfer for the treatment of obesity in adolescents. BMJ Open 2019;9:e026174. [PMID: 31005929 DOI: 10.1136/bmjopen-2018-026174] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
59 Mandato C, Di Nuzzi A, Vajro P. Nutrition and Liver Disease. Nutrients 2017;10:E9. [PMID: 29295475 DOI: 10.3390/nu10010009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
60 de Sant'Ana LP, Ribeiro DJS, Martins AMA, Dos Santos FN, Corrêa R, Almeida RDN, Eberlin MN, Maurice CF, Magalhães KG. Absence of the Caspases 1/11 Modulates Liver Global Lipid Profile and Gut Microbiota in High-Fat-Diet-Induced Obese Mice. Front Immunol 2019;10:2926. [PMID: 31998283 DOI: 10.3389/fimmu.2019.02926] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
61 Ji Y, Chung YM, Park S, Jeong D, Kim B, Holzapfel WH. Dose-dependent and strain-dependent anti-obesity effects of Lactobacillus sakei in a diet induced obese murine model. PeerJ 2019;7:e6651. [PMID: 30923658 DOI: 10.7717/peerj.6651] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
62 Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E. The role of the microbiome in NAFLD and NASH. EMBO Mol Med. 2019;11: e9302. [PMID: 30591521 DOI: 10.15252/emmm.201809302] [Cited by in Crossref: 131] [Cited by in F6Publishing: 121] [Article Influence: 65.5] [Reference Citation Analysis]
63 Konturek PC, Harsch IA, Konturek K, Schink M, Zopf Y. [Gut-liver axis: How intestinal bacteria affect the liver]. MMW Fortschr Med 2018;160:11-5. [PMID: 30367438 DOI: 10.1007/s15006-018-1051-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
64 Tan S, Ge W, Wang J, Liu W, Zhao Y, Shen W, Li L. Zearalenone-induced aberration in the composition of the gut microbiome and function impacts the ovary reserve. Chemosphere 2020;244:125493. [DOI: 10.1016/j.chemosphere.2019.125493] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
65 Han R, Ma J, Li H. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota. Front Med. 2018;12:645-657. [PMID: 30178233 DOI: 10.1007/s11684-018-0645-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
66 Hao Y, Liao X, Wang X, Lao S, Liao W. The biological regulatory activities of Flammulina velutipes polysaccharide in mice intestinal microbiota, immune repertoire and heart transcriptome. Int J Biol Macromol 2021;185:582-91. [PMID: 34216660 DOI: 10.1016/j.ijbiomac.2021.06.175] [Reference Citation Analysis]
67 Wang L, Wan YY. The role of gut microbiota in liver disease development and treatment. Liver Res 2019;3:3-18. [PMID: 32461811 DOI: 10.1016/j.livres.2019.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
68 Zhang L, Xie Z, Yu H, Du H, Wang X, Cai J, Qiu Y, Chen R, Jiang X, Liu Z, Li Y, Chen T. TLR2 inhibition ameliorates the amplification effect of LPS on lipid accumulation and lipotoxicity in hepatic cells. Ann Transl Med 2021;9:1429. [PMID: 34733981 DOI: 10.21037/atm-21-4012] [Reference Citation Analysis]
69 Huang W, Kong D. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD. Biomedicine & Pharmacotherapy 2021;135:111235. [DOI: 10.1016/j.biopha.2021.111235] [Reference Citation Analysis]
70 Castillo V, Figueroa F, González-Pizarro K, Jopia P, Ibacache-Quiroga C. Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review. Foods 2021;10:1719. [PMID: 34441497 DOI: 10.3390/foods10081719] [Reference Citation Analysis]
71 Maeda T, Miki S, Morihara N, Kagawa Y. Aged garlic extract ameliorates fatty liver and insulin resistance and improves the gut microbiota profile in a mouse model of insulin resistance. Exp Ther Med 2019;18:857-66. [PMID: 31281460 DOI: 10.3892/etm.2019.7636] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
72 Zhou M, Hu N, Liu M, Deng Y, He L, Guo C, Zhao X, Li Y. A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix. Biomed Res Int 2020;2020:5462063. [PMID: 32382557 DOI: 10.1155/2020/5462063] [Reference Citation Analysis]
73 Chen F, Esmaili S, Rogers GB, Bugianesi E, Petta S, Marchesini G, Bayoumi A, Metwally M, Azardaryany MK, Coulter S, Choo JM, Younes R, Rosso C, Liddle C, Adams LA, Craxì A, George J, Eslam M. Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. Hepatology 2020;71:1213-27. [PMID: 31442319 DOI: 10.1002/hep.30908] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 75.0] [Reference Citation Analysis]
74 Weschenfelder C, Schaan de Quadros A, Lorenzon Dos Santos J, Bueno Garofallo S, Marcadenti A. Adipokines and Adipose Tissue-Related Metabolites, Nuts and Cardiovascular Disease. Metabolites 2020;10:E32. [PMID: 31940832 DOI: 10.3390/metabo10010032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
75 Wang Y, Zhou X, Zhao D, Wang X, Gurley EC, Liu R, Li X, Hylemon PB, Chen W, Zhou H. Berberine inhibits free fatty acid and LPS-induced inflammation via modulating ER stress response in macrophages and hepatocytes. PLoS One 2020;15:e0232630. [PMID: 32357187 DOI: 10.1371/journal.pone.0232630] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
76 Crawford MS, Mohr AE, Sweazea KL. Novel Organic Mineral Complex Prevents High-Fat Diet-Induced Changes in the Gut and Liver of Male Sprague-Dawley Rats. J Nutr Metab 2020;2020:8846401. [PMID: 33414960 DOI: 10.1155/2020/8846401] [Reference Citation Analysis]
77 Xu J, Liu T, Li Y, Liu W, Ding Z, Ma H, Seeram NP, Mu Y, Huang X, Li L. Jamun ( Eugenia jambolana Lam.) Fruit Extract Prevents Obesity by Modulating the Gut Microbiome in High‐Fat‐Diet‐Fed Mice. Mol Nutr Food Res 2019;63:1801307. [DOI: 10.1002/mnfr.201801307] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]